MARKET WIREYahoo! Finance Canada • 7h ago
PetMed Express, Inc. (PETS) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
Why PETS Stock advanced +0.85% Today — RQD Quant Desk Flash
$1.19 +0.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.19
PetMed Express Inc. (PETS) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $25.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PETS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PETS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, PetMed Express Inc. (NASDAQ: PETS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $1.19 (+0.85% 1D, market cap $25.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 146 tracked Consumer Staples issuers, PETS ranks #145 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PETS compare to YI and RDGT in the Consumer Staples sector?
▼
Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), PETS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -35.0%. By comparison, YI (111 Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.5%, cap $26.2M) and RDGT (Ridgetech Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC —, cap $3.0M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PETS?
▼
Per PETS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001040130), PetMed Express Inc. generated $179.0M in revenue (-21.1% YoY), -$57.3M in net income, and -$33.0M in free cash flow against $88.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.19 (-0.04%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-17.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PETS)Realized 20D OHLCV Swing Band: ±7.8%
Deterministic 5-Pillar Attribution (19/100 Composite)
🔍 WHY PETS SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+6/20 pts (32% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.1 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 28.1% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.26-8.7% Next Q
27
Q2 (-2Q)Grade E$1.15+0.9% Next Q
24
Q3 (-1Q)Grade E$1.16+2.6% Next Q
22
CurrentGrade E$1.19-12% Hist 90D α
19
Trajectory: E (27) → E (19)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PETS Turnaround Squeeze
While PETS currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Consumer Staples with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.47) and Max Pain ($1.25) forces dealer call-delta covering toward $4.30.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PETS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PETS Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PETS Stock advanced +0.85% Today — RQD Quant Desk Flash
PetMed Express Inc. (PETS) advanced +0.85% to $1.19, trading at 2% of its 52-week range ($1.15 – $4.1). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.15 – $4.1) with RSI-14 at 33.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.8% around $1.19 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 28.1% gross margin and $0 annual free cash flow.
Live PETS Headlines & Catalysts
MARKET WIREStock Titan • 10h ago
A live webcast will cover PetMeds' results on Nov. 10 at 4:30 p.m. ETStock Titan report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 13h ago
Pet Service Holding NV Announces the Availability of the 2026 Half-Year Financial ReportYahoo Finance report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com UK • 16h ago
Form 4 PetMed Express Inc: Jeffrey Allen Willard (Director, CEO and President) For: 28 SeptemberInvesting.com UK report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
CATALYSTad-hoc-news.de • 19h ago
PetMed Express stock gains 4.35 percent on Nasdaq. Morgan Stanley holds USD 1.40 targetad-hoc-news.de report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 22h ago
PetMed Express (PETS) Ticks Higher to $1.19 as Traders Eye $1.13 Support - IV Spikehttps://www.dars.gov.et/ report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 1d ago
PETS Q3 2026 Earnings: Reported Loss of $0.28 Per Share Falls Well Short of Consensushttps://www.dars.gov.et/ report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 6d ago
PetMed Express, Inc. to Report Second Quarter Fiscal Year 2027 Financial Results on Tuesday, November 10, 2026DELRAY BEACH, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the second quarter fiscal year
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PETS)
- ✓Walkthrough of PETS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PETS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.58%▼ DESCENDING CHANNEL
2026-11-02O $1.19H $1.19L $1.18C $1.19VOL 12.5K
RES: $1.49SUP: $1.04SMA50: $1.47SMA200: $2.10
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PETS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -21.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PETS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PETS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PETS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PETS)
Consumer Staples Rank #145 of 146
⚔️ YI vs PETS Full Matrix →
1. Head-to-Head Consumer Staples Peer Comparison (PETS vs. YI, RDGT, GRDN, CVS)
Industry: Retail-Drug Stores and Proprietary Stores (5 Tracked Issuers)Across 146 tracked Consumer Staples securities in the Roarable RQD universe, PetMed Express Inc. (PETS) ranks #145 by composite RQD confidence (19/100, grade E) and #117 by equity capitalization ($25.6M). Within this direct 5-issuer industry benchmark cohort, GRDN leads on earnings valuation at 52.1x trailing P/E, while GRDN leads on capital efficiency and profitability with 37.7% ROIC and 20.2% gross margin. GRDN currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with PETS at 19/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PETS
ACTIVE
PetMed Express Inc. | E | 19/100 | — | 28.1% | -35.0% | +0.85% | $25.6M | Benchmark Subject |
| YI 111 Inc. | D- | 37/100 | — | 5.8% | -20.5% | -4.36% | $26.2M | /yi-vs-pets → |
| RDGT Ridgetech Inc. | D- | 37/100 | — | 3.6% | — | -3.32% | $3.0M | /rdgt-vs-pets → |
| GRDN Guardian Pharmacy Services Inc. (Class A) | B- | 71/100 | 52.1x | 20.2% | 37.7% | +0.59% | $2.56B | /grdn-vs-pets → |
| CVS CVS Health Corporation | C- | 61/100 | 65.3x | 45.0% | 2.6% | -0.09% | $115.53B | /cvs-vs-pets → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001040130In its most recent audited fiscal period (FY2025, filed 2026-03-31), PetMed Express Inc. (PETS) reported GAAP revenue of $179.0M (-21.1% vs. FY2024 revenue of $227.0M , and -34.7% cumulative change since FY2023) , GAAP net income of -$57.3M, operating cash flow of -$28.4M, and free cash flow of -$33.0M (-8256.7% YoY). On the balance sheet, PETS closed FY2025 with $88.0M in total assets against $0 in total debt (Altman Z-Score: 0.24, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-03-31 | $179.0M | -$57.3M | -$28.4M | -$33.0M | $88.0M | — |
| FY2024 (FY) | 2025-03-31 | $227.0M | -$6.3M | $4.7M | -$395.0K | $144.8M | — |
| FY2023 (FY) | 2024-03-31 | $274.1M | -$7.5M | $4.3M | $4.3M | — | — |
3. PETS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PETS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, PetMed Express Inc. (NASDAQ: PETS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $1.19 (+0.85% 1D, market cap $25.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 146 tracked Consumer Staples issuers, PETS ranks #145 in composite RQD confidence.
How does PETS compare to YI and RDGT in the Consumer Staples sector?
Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), PETS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -35.0%. By comparison, YI (111 Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.5%, cap $26.2M) and RDGT (Ridgetech Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC —, cap $3.0M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PETS?
Per PETS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001040130), PetMed Express Inc. generated $179.0M in revenue (-21.1% YoY), -$57.3M in net income, and -$33.0M in free cash flow against $88.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PETS trading relative to its 50-day, 200-day, and 52-week technical levels?
PETS last traded at $1.19 (+0.85% on volume of 42,359 shares), positioning the stock -19.05% below its 50-day simple moving average ($1.47) and -43.33% below its 200-day simple moving average ($2.10). Across its 52-week range of $1.15 to $4.10, PETS sits at the 1.4% percentile with a 14-day RSI of 33.1 (NEUTRAL RANGE) and an implied next-earnings move of ±7.8% ($1.10 to $1.28).
PETS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PETS stock moving today?
Why PETS Stock advanced +0.85% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 19/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
PETS — PetMed Express Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:49:19Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, PETS carries an RQD Score of 19 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 5 of 20 (ROIC of -35%; FCF yield of 0%), indicating the business is not currently converting capital into returns or free cash. Whale/13F Flow scores 3 of 20 on institutional accumulation and options positioning, suggesting limited institutional support. Insider Conviction scores 3 of 20 on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 6 of 20, reflecting a Beta of 1.0 and sector sensitivity. Forensic Balance Sheet scores 2 of 20, with an Altman Z of 0.24, a Piotroski F of 2/9, and a Debt/Equity of 0.5. For a prospective investor, the upside case rests on any reversal in cash generation, which the rating does not show as currently present. The valuation tradeoff is that a $1.18 share price against a $25.6M market cap sits within a 52-week range of $1.15 to $4.10, and the forensic pillars indicate elevated distress risk. Second-order implications are that weak balance-sheet metrics can constrain strategic flexibility even if operating conditions stabilize.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $179.0M | $-58.7M | $-57.3M | N/A | $-33.0M | $26.9M | N/A |
| FY 2024 | $227.0M | $-1.5M | $-6.3M | N/A | $-0.4M | $50.1M | N/A |
| FY 2023 | $274.1M | $-8.2M | $-7.5M | N/A | $4.3M | N/A | N/A |
Per the SEC financials, revenue declined from $274.1M in FY 2023 to $179.0M in FY 2025, while net losses widened to $-57.3M in FY 2025. Per the market data, gross margin is 28.1%, operating margin is -32.8%, and net margin is -32%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.24, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Cash declined from $50.1M in FY 2024 to $26.9M in FY 2025 alongside negative free cash flow of $-33.0M.
Recent Catalysts & News Wire Analysis
Per the recent news feed, a live webcast covering PetMeds results is scheduled for Nov. 10 at 4:30 p.m. ET, which is the most concrete near-term event in the source data. A Form 4 filing by Jeffrey Allen Willard (Director, CEO and President) dated 28 September is referenced. One headline reports the stock gaining 4.35 percent on Nasdaq alongside a Morgan Stanley target of USD 1.40, flagged as a catalyst. Another headline references traders eyeing $1.13 support with an IV spike, a technical item. Several feed items are generic market-wire entries with no substantive content. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links or proprietary signals.
Open Questions
- What drove the revenue decline from $274.1M in FY 2023 to $179.0M in FY 2025, and is it expected to continue?
- What are the drivers of the FY 2025 net loss of $-57.3M, and is there a path to positive operating income?
- What is the composition of the $26.9M cash balance relative to the FY 2025 free cash flow burn of $-33.0M?
- What are the terms and amount of debt, given that the debt field is reported as N/A for all periods?
- What do the forthcoming Nov. 10 results disclose about trajectory, and how does the Form 4 activity relate to them?
PETS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for PetMed Express Inc. (PETS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 7h ago
PetMed Express, Inc. (PETS) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 10h ago
A live webcast will cover PetMeds' results on Nov. 10 at 4:30 p.m. ET Stock Titan report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 13h ago
Pet Service Holding NV Announces the Availability of the 2026 Half-Year Financial Report Yahoo Finance report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 16h ago
Form 4 PetMed Express Inc: Jeffrey Allen Willard (Director, CEO and President) For: 28 September Investing.com UK report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST ad-hoc-news.de • 19h ago
PetMed Express stock gains 4.35 percent on Nasdaq. Morgan Stanley holds USD 1.40 target ad-hoc-news.de report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 22h ago
PetMed Express (PETS) Ticks Higher to $1.19 as Traders Eye $1.13 Support - IV Spike https://www.dars.gov.et/ report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago
PETS Q3 2026 Earnings: Reported Loss of $0.28 Per Share Falls Well Short of Consensus https://www.dars.gov.et/ report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 6d ago
PetMed Express, Inc. to Report Second Quarter Fiscal Year 2027 Financial Results on Tuesday, November 10, 2026 DELRAY BEACH, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the second quarter fiscal year
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PETS Bull vs. Bear Conversation Board — What's Your Call at $1.19?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PETS 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $1.04 (-11.9%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is PETS (E • RQD 19/100) a Buy at $1.18?
Welcome to the PETS (PetMed Express Inc.) Roar Pit. Current RQD Composite is 19/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Retail-Drug Stores and Proprietary Stores. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.97 (-17.8%)
Spot @ $1.18 Pump the brakes on PETS — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on PETS, but look at what you are paying: current EV/EBITDA multiples with 28.1% gross margins. Unless PetMed Express Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CA CashFlowKing Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1.43 (+21.2%)
Spot @ $1.18 PETS cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on PETS, the market is fixating on short-term headline noise in Retail-Drug Stores and Proprietary Stores and ignoring the balance sheet and cash flow trajectory. At $1.18 (52-wk range $1.15 - $4.10), any beat on forward guidance forces shorts and underweight funds to chase.